This study explored the impact of atogepant-based preventive care on overall well-being, everyday activities, and the burden of headaches across the migraine continuum.
Preventive therapy with atogepant 60 mg once daily effectively reduces migraine-related disability, improves daily performance, and enhances overall well-being.
This study explored the impact of atogepant-based preventive care on overall well-being, everyday activities, and the burden of headaches across the migraine continuum.
Using data from three 12-week randomized trials investigating a single daily dose of atogepant 60 mg for migraine prevention, patient-reported outcomes were analyzed. The ADVANCE trial included volunteers with low-frequency (4–8 monthly migraine days [MMDs]) and high-frequency (8–14 MMDs) episodic migraine. The PROGRESS trial focused on chronic migraine, while ELEVATE examined episodic migraine in individuals who had failed two to four classes of oral preventive therapies.
Prophylactic treatment with atogepant markedly outperformed placebo across multiple measures. At week 12, improvements in Migraine-Specific Quality of Life (MSQoL) Role Function–Restrictive domain scores were observed, with least squares mean differences of 12.0 and 9.9 for low- and high-frequency episodic migraine in ADVANCE, 6.2 in PROGRESS, and 17.7 in ELEVATE.
Headache Impact Test-6 (HIT-6) scores also improved, with reductions of −4.7 and −3.4 in ADVANCE, −2.8 in PROGRESS, and −6.5 in ELEVATE. Activity Impairment in Migraine–Diary-Performance of Daily Activities scores exhibited similar benefits, with reductions of −2.3 and −4.5 in ADVANCE, −3.4 in PROGRESS, and −4.7 in ELEVATE.
Preventive use of atogepant 60 mg daily supported better migraine-related quality of life and functional improvements, regardless of headache frequency or past treatment failures.
Cephalalgia
Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials
Christopher Gottschalk et al.
Comments (0)